A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes

被引：0
|
作者：
桂晓敏 [1 ]
机构：
[1] Dept Hemato,1st Affil Hosp,Soochow Univ
来源：
China Medical Abstracts(Internal Medicine) | 2014年 / 31卷 / 02期
关键词：
BCR; A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes; CML; ABL; gene;
D O I：
暂无
中图分类号：
R733.7 [白血病];
学科分类号：
摘要：
Objective To explore the clinical and laboratory features of chronic myeloid leukemia(CML)with atypical e14a3 and e19a2 BCR-ABL fusion gene subtypes.Methods We retrospectively analyzed a cohort of CML patients with Ph chromosome positive confirmed by cytogenetic and FISH but classical e13a3(b2a2),e14a2(b3a2)and e1a2 fusion transcripts negative identified by
引用
收藏
页码：122 / 123
页数：2
相关论文
共 50 条
  • [31] CLINICAL DETECTION OF BCR-ABL FUSION BY INSITU HYBRIDIZATION IN CHRONIC MYELOGENOUS LEUKEMIA
    AMIEL, A
    YARKONI, S
    FEJGIN, M
    GABER, E
    NAGLER, A
    MANOR, Y
    LISHNER, M
    CANCER GENETICS AND CYTOGENETICS, 1993, 65 (01) : 32 - 34
  • [32] Molecular deregulations mediated by Bcr-Abl in chronic myeloid leukemia
    Chomel, JC
    Guilhot, F
    Tanzer, J
    Kitzis, A
    M S-MEDECINE SCIENCES, 1995, 11 (12): : 1669 - 1678
  • [33] Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia
    Radich, Jerald P.
    CANCER, 2012, 118 (02) : 300 - 311
  • [34] BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
    Loscocco, Federica
    Visani, Giuseppe
    Galimberti, Sara
    Curti, Antonio
    Isidori, Alessandro
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [35] Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia
    Mythreyi Narasimhan
    Vaishnavi Khamkar
    Sarika Tilwani
    Sorab N. Dalal
    Dhanlaxmi Shetty
    P.G. Subramanian
    Sanjay Gupta
    Rukmini Govekar
    Journal of Cell Communication and Signaling, 2022, 16 : 207 - 222
  • [36] Impact of BCR-ABL mutations on patients with chronic myeloid leukemia
    Hochhaus, Andreas
    La Rosee, Paul
    Mueller, Martin C.
    Ernst, Thomas
    Cross, Nicholas C. P.
    CELL CYCLE, 2011, 10 (02) : 250 - 260
  • [37] INHIBITION OF APOPTOSIS BY BCR-ABL IN CHRONIC MYELOID-LEUKEMIA
    BEDI, A
    ZEHNBAUER, BA
    BARBER, JP
    SHARKIS, SJ
    JONES, RJ
    BLOOD, 1994, 83 (08) : 2038 - 2044
  • [38] BCR-ABL ANTISENSE PURGING IN CHRONIC MYELOID-LEUKEMIA
    KIRKLAND, MA
    OBRIEN, SG
    MCDONALD, C
    DAVIDSON, RJ
    CROSS, NCP
    GOLDMAN, JM
    LANCET, 1993, 342 (8871): : 614 - 614
  • [39] Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia
    Menif, S.
    Zarrouki, S.
    Jeddi, R.
    ben Alaya, N.
    Ali, Z. BelHadj
    Ben Abid, H.
    Hdeiji, S.
    Elloumi, M.
    Khlif, A.
    Meddeb, B.
    Dellagi, K.
    PATHOLOGIE BIOLOGIE, 2009, 57 (05): : 388 - 391
  • [40] BCR-ABL targeted therapy in chronic myeloid leukemia (CML).
    Goldman, JM
    Deininger, M
    Melo, JV
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 515 - 515
12345